NETRIS Pharma
Lyon
About NETRIS Pharma
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the pharmaceutical industry. The dependence receptors are trans-membrane proteins that receive signals and transmit them inside cells and this helps in controlling tumor development. The company provides vitro and in vivo research, preclinical practices for manufacturing drugs for the treatment of breast cancer, lung cancer, glioblastoma and neuroblastoma cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $12.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2023)
- Website: netrispharma.com
- Phone: +33 4 78 78 29 53
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/netris-pharma-21067 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.